Abaxis Inc (ABAX): Achim Henkel , Managing Director-Europe of Abaxis Inc sold 5,000 shares on May 17, 2016. The Insider selling transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were sold at $44.42 per share for a total value of $222,153.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Henk Evenhuis (director) sold 3,000 shares at $45.00 per share price.On Feb 11, 2016, Vernon E Altman (director) purchased 303 shares at $39.87 per share price.Also, On Dec 10, 2015, Craig Tockman (VP-Sales & Mktg, Animal Health) sold 560 shares at $54.44 per share price.On Feb 10, 2015, Prithipal Singh (director) sold 2,500 shares at $60.50 per share price.
Shares of Abaxis Inc (ABAX) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.92 points or -2.05% at $44.02 with 1,00,671 shares getting traded. Post opening the session at $44.56, the shares hit an intraday low of $43.62 and an intraday high of $45.2 and the price vacillated in this range throughout the day. The company has a market cap of $996,701 M and the number of outstanding shares has been calculated to be 22,64,20,00,000 shares. The 52-week high of Abaxis Inc is $58.15 and the 52-week low is $37.71.
On Apr 28, 2016, Abaxis Inc announced a cash dividend of $0.1200. The company’s management has announced Jun 1, 2016 as the ex-dividend date and fixed the record date on Jun 3, 2016. The payable date has been fixed on Jun 17, 2016.
Company has been under the radar of several Street Analysts.Abaxis Inc is Reiterated by Canaccord Genuity to Hold while Lowering the Price Target of the company shares to $ 42 from a previous price target of $47 . The Rating was issued on Apr 1, 2016.
Abaxis Inc. is a developer manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company operates through the two segments: the medical market and the veterinary market. The Company’s medical market customer group consists of physicians’ office practices across multiple specialties urgent care outpatient and walk-in clinics health screening operations home care providers and nursing homes. The Company’s medical market products include: Piccolo chemistry analyzers and consumable products. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs VetScan hematology instruments and related reagent kits VetScan VSpro specialty analyzers and related consumables VetScan i-STAT analyzers and related consumables and VetScan rapid tests.